Clinical research

SURPASS-CVOT: Cardiovascular outcomes with tirzepatide

Phase 3 cardiovascular outcomes trial. 13,299 randomised, over Approximately 4.5 years. Sponsor: Eli Lilly and Company.

SURPASS-CVOT (NCT04255433) tested at Maximum tolerated against dulaglutide in .Non-inferior to dulaglutide for MACE. This is not a demonstration of superiority over placebo Unverified — no source on file: the source is a citable record we could not authoritatively link, which we have not independently re-extracted from the full paper in this session.

Study design

Results

Non-inferior to dulaglutide for MACE. This is not a demonstration of superiority over placebo

Adverse events & discontinuations

Not extracted from the source in this session.

Limitations

An active-comparator non-inferiority design. Non-inferiority to another GLP-1 is a different claim from cardiovascular benefit versus placebo, and the two are frequently conflated.

Practical interpretation

This is one trial, reported by Eli Lilly and Company, read directly against the registry and publication linked below — GLP Ranked has not re-run the statistics or obtained the patient-level data. Results describe group averages under trial conditions and may not describe any individual's outcome, including with a compounded, non-FDA-approved version of a similar active ingredient. Always check the primary source before citing a specific number.